30 results about "Hypoxic stress" patented technology

The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.), including stimulation of the hypoxic stress response in tumor cells.

A hypoxic training facility includes a plurality of walls defining an enclosure for housing an animal to be trained. A hypoxicator is adapted for delivering hypoxic, hyperoxic, and normoxic air to the enclosure during a hypoxic training session. An animal exercise station is located within the enclosure. A pulse oximeter monitors oxygen saturation of the animal's blood during the hypoxic training session. A computing device calculates hypoxic stress delivered to the animal during the hypoxic training session.

An object of this invention is to produce a protein by efficiently culturing plant cells while escaping mRNA translational repression in cultured plant cells under stress caused by lack of conditions essentially required for the growth (e.g., nutrient-starvation stress and hypoxic stress). This invention provides a method for escaping translational repression of a protein encoded by mRNA, the repression being induced by stress due to absence of conditions required for the growth, the method comprising the step of culturing a plant cell transformed with a recombinant DNA molecule encoding mRNA containing 5′ UTR defined in (a) or (b) below, the culturing being carried out under stress due to absence of conditions required for the growth: (a) 5′ UTR having a base sequence of SEQ ID NO: 1, 2, 3, 4, 5, or 6; or (b) 5′ UTR having the base sequence of the 5′ UTR of (a) in which one or more bases are replaced, deleted, or added, and which escapes translational repression induced by stress due to absence of conditions required for the growth.

The present invention provides a use of a HIF-2alpha inhibitor in preparation of drugs for preventing and treating acute high-altitude reaction. The HIF-2alpha inhibitor comprises HIF-2alpha-I2 and/orPT2385; the use according to the invention fully investigates molecular mechanisms and key molecular events and processes of acute high-altitude reaction and hypoxia stress, and a series of experiments shows that HIF-2alpha-I2 and PT2385 both can significantly improve the malignant degree and symptoms including slowing shortness of breath, emotional upset, and high heart rate of acute high-altitude reaction, as well as alleviate the acute hypoxic stress response, so as to achieve the purpose of effectively preventing acute hypoxia. The use has good safety, little side effects and other advantages, and has a good application prospect.

The invention discloses SNP (single nucleotide polymorphism) molecular markers related to hypoxia tolerance of rice and application of the SNP molecular markers. The SNP molecular markers provided bythe invention are located at the 30th, 096th and 391st sites of rice chromosome 3, and the polymorphism is A or G. The SNP molecular markers are significantly correlated with the survival rate of riceseedlings under hypoxic stress conditions. A rice variety with a genotype being GG at the sites is significantly stronger in resistance to hypoxic germination than that of a rice variety with the genotype being AA under hypoxic stress conditions. The invention also designs PCR primers based on the SNP sites, and the nucleotide sequences of the primers are shown in sequence 1 and sequence 2. The SNP molecular markers related to the hypoxia tolerance in rice provided by the invention are verified in natural populations that the markers can effectively predict the hypoxia germination tolerance of rice, and thus can be used for marker-assisted breeding of hypoxia tolerance and direct seeding molecular breeding in rice.

Persons with sleep disordered breathing (SDB) may, or may not, recognize that they have symptoms of SDB, and/or that they may be at-risk of, or suffering certain health problems associated with SDB, including death. The disclosed Energy Conversion Monitor (ECM) sensor, when embodied, for example, in a wearable upper-armband format, has been demonstrated to be more sensitive and responsive than pulse oximetry monitoring of blood oxygen saturation as an indication of hypoxic stress induced by SDB, and is compatible with: (1) inclusion in sleep laboratory polysomnograph (PSG) testing instrumentation, (2) home-based diagnostic testing for SDB, (3) control of home-use airway therapy devices, (4) continuous remote surveillance and refinement of airway therapy, and (5) spot-check and continuous surveillance of sleep quality in the general population. The disclosed ECM also provides new measurements of physiologic stress during and following exercise. When applied during initial care of premature newborn infants, it offers improved therapeutic guidance during their transition from their limited in utero oxygen supply conditions, to the increased oxygen availability from breathing air. When applied during resuscitation of persons suffering from hypoxia and during reperfusion of ischemic tissue, such as during treatment of ischemic stroke, or ischemic heart attack, the ECM sensor can provide objective guidance regarding the safe and effective resupply of oxygen to the hypoxia-adapted tissue to help reduce or prevent microvascular occlusion and cellular injury. As a continuously worn physiologic surveillance monitor, the ECM offers the potential of early detection of sepsis. For the elderly and infirm, the ECM offers a convenient and comfortable means of continuously assessing variations in status while awake and asleep.

Provided are methods for inhibiting cancer cell growth comprising contacting the cancer cell with an agent which inhibits the expression of the gene, or the activity of, apolipoprotein B editing catalytic 3G (APOBEC3G). Also provided are methods for identifying agents which can induce or inhibit C>U deamination in RNA driven by apolipoprotein B editing catalytic proteins. The method comprises contacting APOBEC3G with a suitable RNA substrate and determining the extent of C>U deamination under conditions which induce APOBEC driven C>U deamination.

The invention belongs to the technical field of sprouted grains and relates to an industrial production method of sprouted millet. Shelled millet are placed in a sprouting device; hypoxic stressed sprouting is carried out at 0-40 DEG C for 21-32.5 h; an accelerating liquid, a regulating agent and a bactericide are sprayed to the sprouting device at intervals of 30-40 min; after sprouting, cleaningand drying are performed to obtain sprouted millet. The method of producing sprouted millet is initiated herein; efficient high-quality sprouting is achieved for millet; the grown sprouted millet hassprouts reaching 1-2 mm in length; nutritional value and bioactivity of millet are greatly improved; a new chapter of sprouted grains is explored.